PAUTLER, COHEN, FINDLAY, EICHENBAUM, WHITE & CRANE MD'S PA

OTX-TKI, an intravitreal implant containing axitinib, significantly reduced injection frequency by nearly 90% in wet AMD patients, with stable visual acuity and central subfield thickness outcomes compared to aflibercept. The phase I study showed a favorable safety profile and potential durability of up to 12 months. Phase III studies SOL-1 and SOL-R aim to assess durability and repeat dosing, potentially leading to reduced treatment burden for patients.

Oculis announces updates on the DIAMOND Phase 3 program with OCS-01 for DME, to be presented at Innovate Retina and Eyecelerator 2024. The program aims to assess the efficacy and safety of OCS-01 eye drops in DME at Week 52, with both DIAMOND-1 and DIAMOND-2 trials enrolling 350 patients each. Additionally, Oculis anticipates topline results from the ACUITY Phase 2 trial with OCS-05 for acute optic neuritis by the end of 2024.